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I

"An 1ntroduct1on to intensive
therapy of eypq111e w
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The Renaissance of 1nterest 1n syph111s which
occurred between 1905 and- 1910 was brought about
through the dlscovery of the causative organism by
Sehaudinn, the diagnostic serological test by
Wassermann, and the potent ant1-�yph1l1t1c drug
A.rsphenam1ne by Ehrl1qh.

By �he proper-use of these

three aids, the two objectives of therapy of early
syph1l1s, control of 1nfect1ousness and radical �ure
can be realized.

For example, the darkf1eld exam1n

at1on allows recognition of the disease, before the
Wassermann test becomes positive, ·and permits insti
tution of therapy during the seronegat1ve primary
stage, the period of "Golden opportunity." (21)
Ehrlich and his co-workers after diligent re
search, finally discovered arsphenam1ne 1n 190?, 1t
being the 606th product investigated, it was popular
ly called 606.

It came into wide use in syph1lotherapy

1n 1909-1910 and treatment wlth_ this drug was based
on Ehrl1oh's concept of "The�ap1a Ster111eana Xagna,"
that is, therapeutic sterllization of the body after
a few large doses of the drug.

Unfortunately this was

not true, a,t the time, for arsphenamlne, and it was
not appreciated until some years later, that with the
teehn1que 1n vogue then, many months of continuous
treatment are necessary to control syphilis.
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Within a year of the discovery of Salvarean, lt
became evident that a single dose was not curative
for syphilis.

Attempts were thereupon made, to bring

about a rapid cure by means of a short intensive
chemotherapeutic attack.

As early as 1910, Hof:fmann

attempted mod1f1cat10.ns of this plan of treatment,
but 1t was not tried on a large scale untll 1916 when
Poll1tzer suggested a plan of treatment for early syphl
lis which required the daily adm1n1strat1on for 3-4
days of large doses (.5-.6 gm.) of arephenamine.
Following publication of Pollltzer's results, the scheme
of treatment he proposed was extensively tried by a
large number of workers.

It soon became evident how

ever, that the majority of the patients treated by this
method later developed 1nfect1ous mucoeutaneous relapse
or later progression, particularly in the central
nervous system.
The results of various mod1f1cat1ons of the so
called "abortive" treatment of early syph1l1s was
eummarlzed 1n a condemnatoryfashion by Werther·(1928).
However, Pollitzer's method especially continued 1n
vogue in some places until 1932 when the results of
the study of the treatment of early syphilis by the
Cooperative Cl1n1c Group appeared.
of this study was 1ncluden

In the material

comparison of the results
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of the Pollltzer method with c onventional contlnu
ous, intermittent and irregular treatment sc�edules.
The Poll1tzer method comprlses the use of .6 gm. of
arsphenam1ne every day for 3-4 days, alternating
with a more or less prolonged heavy metal series.
The results followlng the Pollitzer method were as
poor as those of haphazard or irregular treatment. (44)
Considerable harm can be done by uslng an improper
technique to 1nject a few doses of arephenam1ne and
d1emiss1ng the patient as cured when the Wassermann
reaction becomes negatlve, or visible lesions heal.
No treatment at all, may be better than poor therapy.
Poor therapy allows a higher incidence of serious
late lesions, and these appear earlier than they
would otherwise.

Furthermore infectious relapses and

serious neuro-recurrences are the price of poor treat
ment.

The chance of the patient curing himeelf by

hls own 1mmunolog1cal defense mechanism is decreased
by 50% through inadequate medication. (21}

It is un

fair to the patient and to the community at large, to
allow the parctice of poor treatment to exist, since
through its inadequacy, many new cases w1ll appear,
through unrecognized lnfect1ousness.

Many medical

crises will d�velop 1n later life due to the supposedly
cured disease, and faith 1n treatment will be destroyed.

-4-

The suggest1on, somewhat along the 11ne of
Ehrlich's original plan and along the ideas developed
by Pollitzer, that very large doses of arsenlcals
might be given with safety 1n the treatment of syph.l.lie
was first made by Dr. Louis Chargtn; eyphilolog1st at
Mount Sinai Hospital.

Dr. Chargin first obta1ned the

idea of treating eyphilia in this way, _when he read of

the work of Hirschfeld, Hyman and Wagner, who observed
that "speed shock" could be prev�nted by very slow
intravenous administration (60-90) drops per minute.
(25}

Thie work had been done 1n 1931, and 1n an article

by Hyman in 1935, he demonstrated that the rapid I.V.
introduction of pharmacologically active or inert
chem1cals, drugs and biologic fluids might glve rise

to alarming, and at times fatal symptoms, this is the
"speed shock" syndrome.

It was further shown, that

highly toxic substances could be administered safely
by a slow continuous I.V. drip. (9)

Real1z1ng the

toxicity of the arsen1cals, the difficulties of
Pollitzer, the progress 1n treatment methods, and
the introduction of neo-arsphenamine, he decided to
take under experiment the massive dr1p treatment of

ayph111s.
In announcing the new concept of treatment,
Drs. Charg1n, Hyman, Letter and co-workers made it

-5known that this massive dose, short term treatment
of syph1lis was an attempt on the1� part to treat the
primary and ea�ly secondary stages of the disease by
means of massive doses of neo.arepbenam1ne end later
on llaphareen, glven over a few days by continuous
intravenous drip, without subsequent.antisyph1.l1t1c
therapy. (60)
Their treatment involved the 1ntravehoua 1nject1on of flve to six times the usual maximum therapeutic
dose of neo-arsphenamine or ten to fifteen times the
comparable d-0se of Jlapllarsen during a period of 4-5
days.

The 1nject1on continues for fifteen hours a

day.

The immediate clinical and serologic results

obtained in a 11ml ted series of patients (394·) were
quite fav�rable.

However, the 1nc1dence of untoward

reactions was high, particularly peripheral neuritis,
fever, hemorrhagic encephalitis and tox1codermae.
The great public health and economlc advantage of
such therapy was evident, but considerably more con
trolled clinical and experimental study wae necessary
to determine the late clinical results to be expected,
and the hazards of the toxic reactions that might make
their appea�anee.

It had not as yet been determined

if some areenical, leas useful under their aystem"of
therapy might b-e adv-anta�sly emp1-oyed in the in-
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tensive treatment method with greater succese.
The treatment required one full week of hosp1tal1zat1on.
Since the firet investigative days, though only
a short while ago, great strides have been made 1n the
field.

The work done.on massive dosage problems has

been tremendous.

A history of the progress of this

work 1s revealed by a consideration of the methods

of treatmen� evolved and in use at the present time.
These will be taken up 1n deta11 1n a later chapter.
The methods in use up to the present time, are;

1) The slow continuous drip, as practiced in
New York Ci-t-y.
2) The rapid intravenous dr1p, scheduled for
Detroit.

3-) The multiple injection technique of 'themas
and Schoch.

4) Fever therapy plus multiple injections of
Thomas, Simpson.
5) One day fever and Vaphareen of Jones,·
Carpenter, Boak, Warren and Hanson.
6) One day fever, arsenic and bismuth of
Simpson.

1) Pen1elll1n treatment as proposed by Jla.honey.

·,

-7All of these methods have been tr1ed, quite ex
tensively, w1th the exception of the last, and have
been found to be e:tuite eu.ccessful.

N'a.turally, the

later ones have fewer failures, due to the perfection
of f1ner techniques, which are necessary to make thls
method a success.

II

•'l'he value �d .pharmacology of
arsen1eals used 1n intensive
the�apy; with a d1�cuse1on of
the superiority of Maphar&en
and 1ts role 1n the success
of intensive therapy"
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Historically, as we have seen 1n the introducto
ry obapter, massive dose therapy has not been a
re�ent aqu1s1t1on of the profession.

It was tried

almost from the.beg1nn1ng of the arsen1cal treatment
of syphilis.

It has however been a successful method -

of treatment only recently.

Why is this?

It cannot

be attributed entirely to the recent perfection of
new techniques.

There must be some other £actor that

enters lnto the picture and demands consideration.
Wise and Selzberger, editors of the Yearbook of
Dermatology and Syphilology, have recently called
attention to the possibility that the value of the
newer 1ntens1ve methods of treatment may depend not
so much on the 1mporvement in the method of adm1n1et
rat1on, as on the superiority of lla.pharsen over the
other ant1-syphil1t1c arsenicals.(?6)
Levin and Keddie (46) state that Jla.pharsen is less
toxic than neo-arephenamtne.

Only six fatal1t1es from

1lapharsen have been reported slnce 1935.

This rate 1e

remarkable low, considering that over 12 m1111on
ampules have been manufactured.
Death was due to kidney damage and aplaet1c anemia
1n two cases each, and to hemorrhagic encephalitis
and acute agranulocytoeis in one case each.
Seven patients with thrombocytopen1c purpura and

,I

_9 .,.

two with granulocytopen1a from neoarephenamlne tol
erated Jlapharsen without reaction.

Iapharsen may

occasionally cause severe damage to the hemopoet1e
eystem.
Careful observation of the use of llapharsen by
the intravenous rout-e, showed that llapharsen causes
fewer and milder toxic reactions than neo-arsphenamlne.
The United States Navy etat1stiee on reactions to neo
arsphenamln� and to }[apharsen among patients of com
parable age, sex and-general cond1t1on of health lndloa.te
that Kaphareen is def1n1tely less toxic. (46)
After readlng the above, lt is ha�d to believe
that Xagnuson (36) could report such deflnite toxicity
for Kapharsen.

Through experiments with dogs, he found

definite toxic reactions.

Perhaps this ls where the

trouble lies, since all of the previous toxicity ex
periments had been run on rabbits.

Perhaps he is

comparing his dog experiments to the results of the
rabbit experiments.

Another factor 1n hls concluslons

may be, that he refuse� to take into conslderatlon
the high therapeutic efficiency of llapharsen over
neo-arsphenam1ne, and bases his conclus19ns on mere
mass comparison.

'

To contrast Magnuson's experimental findings, a
cl1n1cal report, (60) states that conclusive proof
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of the non-toxic character of llapharsen hae been
demonstrated 1n an uneventful serles of 275 cases.
So an analysts of his artiole,m1�t lead one to
belleve that he drawe erroneous conclus1ons, ;and·.
that 1fapharsen is not the toxlc drug he states it ls.
llaphar$en (arsenox1de) was 1nvest1gated by
Ehrlich and Hata, but pronounced by them to be toe
toxic for clinical use, the high therapeutic eff1e1ency
of the drug not being appreciated. The chemical re
mained of great therapeutic interest however, because
it was believed to be the ox1datlon product through
which the arsphenamlnes exerted their sp1rochetlc1dal
action 1n the body.
After several yearcs of careful la.boratory and
clln1eal research on the ant1-syphll1t1c use of
arsenox1de, cautious reports of 1ts value began to
appear, (68) and the drug was released- for study to
the cooperatlve ol1n1cal group.

The available

evidence indicates that th1s drug is one of the most

-

prom1s1ng arsen1cal trep9nem1cides for syphllotherapy.
The term arsenoxide 1s really a generic one, but

it is used 1n cl1n1cal literature to signify a par
ticular chemical, meta-.amlno para-hydroxy phenl
ars1ne oxide.

From the ftrst letters 1n the component

parts of this chemical name is derived the term
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"llapharsen."

The drug ls not an -arsphenamine but

repreeente a partial ox1dat1on product of arsphenam1ne.
ll'apharsen contains 29% of a trlvalent arsenic
and 1s :marketed as the heml-alooholate in n1-trogen
filled ampules.

The physical and chemical properties

of arsenoxlde are such that, 1n contrast to the ar�
phenam1nes, the drug 1s neither Qreclpitated by t1esue
flu1ds-, nor does 1t agglut1na.te or hemolyze red blood
Ce116 • :( 22 )
The dose of Mapharsen ·1s one tenth that of .. ars
phenam1ne.

The average 1n1t1al adult dose 1a· 40 mg.

for males, and 30 mg. for females.

The absolute amount

of arsenic given 1n a course of Mapharsen 1s only one
tenth the amount given in a course of arsp��nam1ne.
cumulative arsen1cal po1eon1ng ls therefore much less
11-kely; and since only one tenth, of arsphenamine 1s
converted- to arsenox1de 1n the bed:;, (5-5) the therapeutic
dose of the tw-0 are equa11y effective fro.m the stand�olnt

of the end product.

Arsenox1de ha,s the added advantage

of havlng no acet:,mpany1ng break-down products which
must be eliminated by an al.!eady oYertaxed-�yete�,
such as 1s the case with arsp�enarn1ne.

Although the

toxicity of Mapb.a.rsen is about s1x tlmes greater than
that of arspl1enamine, 1 ts clinical eff1c1ency on the
basis of arsenic content is about e1x times as gre�t.
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Although ail the ev:1dence is not yet available,
llapharsen appears to be superior to neo-arsphenam1ne,
and approaches arsp enam1ne 1n the ablll ty to cause
disappearance of the surface treponemes, heal surface
lesions, and effect reversal of the Wassermann reaction.
It is dlrectly spirochet1cida1 and 1s not dependent on
the intermediary breakdown products for lts acltivity.
In fact it ie believed by some to be the substance by
means of �hieh the arsphenamines aet as spirochet•
1c1des and trypanoc1des.
)[apharsen is well tolerated 1n the body, gastro1ntest1n,._1 upsets are fewer, and the drug 1s less
l1kely to make the patient 111.

The patient 1s thus

more willing to cooperate and continue therapy.
N1tr1toid reactions to Mapharsen do not occur.

It can

often be used in full doses 1n patients intolerant
to arsphena.m1nes, and appears to cause?, lower lnoi

dertce of serious skin and visceral reactions.

There

1s some evidence that excretion may be more rapid
than that of the ars»�enam1nes, (80� excreted within
one week), and that 1la_pharsen may therefore be glven
twice weekly. (22)

III

�l
"Establ1sh1ng an expe.r1�ent
ive
ens
int
of
use
the
basis for
"
man
therapy 1n
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Any new method introduced 1nto the field of med.:
lc1ne should be tried first experimentally to prove
1ts worth, 1n so far ae 1s possl'ble 1n the laboratory.
It ls 1n the laboratory that mistakes are discovered
1n techniques, drugs and methods; but the laboratory
can only show results under controlled cona1t1ons.

In

chemotherapy the optimum therapeutic result 1s obtained
by the introduction of the specific agent in quantities
that suffice to des�roy noxious invaders without
ser iously or permanently injuring the cells of the
host.

Under controlled conditions this ldeal is ap

proached ln experimental animals that have been in
fected with syphilis 1n the laboratory; and then pro
mptly treated w1th arsphenam1ne.
In human syphilis the problem offers far greater
difficulties; treatment ls delayed, the dosage must
be agumented, idiosyncrasies are encountered, there
occur techn1eal errors in adm1n1strat1on of the drug.
and untoward reactions may £ollow, vary1ng from mild
and transitory distrubanoes

to

fatal poisoning. (9)

Still 1t 1s necessary to conduct laboratory
experiments with a proposed treatment sueh as th1s.
Laboratory animals must �e chosen for spec1f1e reasons
in teat1ng any new dl'llg
the animal of

·or procedure.

cno1ce was the rabbit.

In :this case
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It is possible in the rabbit to study the dis
appearance of surface organisms, the rate of healing
of lesions, a.nd, by me ans of lymph node and tissue
transfers to normal animals, the actual sterllizatlon
of the 1nfect1 on.

The results should be expressed ln

terms of' the smallest slngle dose {1n milligrams p-er
kilogram) capa.ble of sterilizing the experimental
animal, thus permitting, wben compared w1th the
maximum tolerated dose, an expression of the ther
apeutic index.
This type of study is time consuming, requtr1ng
several months for completion, costly, and not exactly
translatable to human syphll1s, 1n the sense that since
syph111s 1n the rabbit is easier to cure than syph111B
in humans the optimum dosage 1n the rabbit ls not
capable of' d1reot translation into cl1mtcal practice
with equal prospect of success.

But it provides 1n

format1on so valuable, espeo1ai1y as �onoerne the
relative worth of different drugs, that it must be
carried out with every new product proposed; and shou1d
be carr1ed out fro m time to time for a routine testing
of fresh lots of various drugs, already 1n a.cutal use,
to make sure that their therapeutic potency 1a maintained.

(44)
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The problem of working out the experimental
evaluat1on of the 1ntens1ve treatment method fell to
Eagle and Hogan, very able me n in the field of ex
perimental medical research.

They thoroughly in

vestigated the problem, all of its various aspects,
and poss1ble mortalities; and after extenelve work,
published their results ln an exten-a1ve record of
experiment.
The first problem they were foreed to settle
was one of tox1c1�y.

Thle involved the tox1clty of

drugs to be used, methods, .and rates of injection.
It was in working out 'this problem that the value of
the time dose relationship was discovered.

As to

the animals toxicity, they concluded that, the
greater the number of 1nject1ons, and the longer the
tlme perlod over which these injections were spread,
the greater the animals tolerance to l(apharsen. (16)
The time dose relationship factors, much dis
cussed by various authors, can best be understood
by reference to the accompanying charts, which more
than clearly explain the results 1n altering either
the time factor, or the dosage of the drug.

The

effects of such alterations can be followed on the
charts, and the reason for many authors untoward
reactions can be under.a:tood on the basis of altering
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either of thees two factors.
Another of Eagle and Hogan's flndings was that,
the curative dose of llapharsen in syphil1tlc rabbits
was affected to a relatively minor degree by varing,

either the total duration of treatment or the fre
quency of 1nject1ons.

1lapharsen administered by

intravenous drip was usually lees effective than Ma.ph

arsen administered over the same time intervals by
repeated syringe injections.

There was a def1n1te

suggestion also that the drug was more effective when
given over a perlod of a few days, than it was when

treatment was spread over a period of weeks, or con
centrated in one day.

As to margin of safety, �n any sshedule of 1n

ject1one, whethe� weekly, tri-weekly, dally, four times

daily or intravenous drip, any desired margin of safety

between the tolerated dose and the therapeutic dose,

can be obtained by suitable prolongation of the time
period of adm1n1strat1on.
The last finding reported by Eagle and Hogan wae
that in the treatment of Rabbit syphilis, treatment
can be condensed wlth safety by 1ncreas1ng the frequen
cy of injections 1f there ls any compensato.ry decrease
in the e1ze of the individual treatment and an increase

in their total number. (15)
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Showing that the margin 0£ safety afforded by
ant1syph111tic treatment in man 1s decreased 1f ln
jections are g1ven at more frequent intervals, with
out chang1ng either their eize or total number.
(The total "curative" dose was f1xed at 25mg.
per kg., 1,500 mg. ln men weighing 60 kg.; and the
maximum tolerated dose 1n rabbits was used to calculate
the margln of safety (1.\\1} afforded by the various
schedules. Each curve 1n the figure gives the estlmated
margln of eafety for a fixed number of treatments, as
affected by the frequeney of injection.)

IV
"What conet1tutee a cure when using
an intensive method of treatment;
can there be an earlier recogn1t1on"
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The duration of treatment in early syph1l1s1
In 1926 Ke1del m ade the statement that when he first
adopted hie plan of treatment, then 1n operation, he
had

no

accurate ldea�how long the treatment;·ahould be

continued.

The evidence provided by patients who

lapsed after varying amounts of treatment made it
obvious that while a few were e�red by one or two
courses, many were not cured.

Inasmuch ae there 1s

no way of differentiating the potentlal cure �rom the
potential failure before treatment is begun, it seemed
certain that the only safe procedure was to treat every
patient up to the point necessary to cure the most
resistant member of the group.

As long as nine years

ago, therefore, we set up as a standard one year's
continuous treatment after the blood Wassermann (and
spinal fluid) had beco�e and h&d remained completely
negative.

The figures justifying this posttion are

shown·ln the accompanying chart. (44)

They are based

on the material of the Johns Hopkins Clinic, and show
quite clearly that the probability of cure rlses from
35% among the untreated patients to 82% follow1ng 20m
or more injections of arsphenamine in conjunction with
bismuth and mercury.

It is indeed unfortunate that no

method exists by which the probable "cures•. after small
amounts of treatment can be picked out before or during
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treat ment.

Th1s hiatus 1n our knowledge is respons-

1ble for the undoubted fact that some pat1ents receive
much more treatment than ls actually nece-asary •. (45)
It is estimated that 500,000 fresh cases of
syphilis are reported to physicians 1n the United
States each year.

Untold numbers remain unreported,

approximately 600,000 advanced cases wh1ch have never
before received treatment report for the first time
each year, and 5-10% of the population are infected.
The dlfflculty lies not 1n a lack of information,
but in the failure both of the phye1c1an and the pub�1c
to use the knowledge already available.
The concept of curability of syphilis varies with
the stage of the disease.
1) Biological or Radical Cure: this s1gn1f1es
erad1cat1pn of the last treponeme from the body, and
applies only to early (primary and secondary) syph111s.
2) Symptomatic Cures applies to late syphilis
and signifies the disappearance of all slgns and
symptoms of the disease and the laok of lnfectiousness.
The organisms are not killed.

The _serology may be

positive or negative, a matter of secondary 1mprotance.
Cure in either sense, can be determlned onl_y by careful
observation over a period of years. (21)
Previously 1t was not as important to know whether

-24-

or not the patient had biologic cure, or merely
symptomatlc cure of syphllls; we were treating wlth
a standard method; we had nothing better to offer the
patient; and we had a long series of time preceding,
ue1ng the same type of treatment, in which to evaluate
its worth.
the patient.

But today we may have something to offer
With our new forms of massive therapy,

we may be able to offer him a fast cure, never before
hoped for.

Whether or not this 1B a positive cure,

we cannot say, because sufficient t1me has not elapsed
from its introduction up to the present time, to speak
properly concernlng its efficacy.

If is 1s positive,

many patients that could have been treated may pass
us by.

The fact that this 1s a tlme of war, when it

would be possible to check more closely in short time
periods large groups, makes it imperative that we cease
judging new treatment on the yardst1ck of the old.
Up to the present time we have been judging its
worth by comparison to methods used in the old, long
treatment method1 and we have been afraid to use the
new treatment, because we could not be sure of its
trua therapeutic effect.

J. E. Moore, 1n an editorial,

expresses a somewhat radical departure from accepted
standards of evaluation when he describes a method of
measur1Dg curability by re-infection. (41)
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..Relapse 1s accepted as a cl1n1cal character1st1c
of syphilis.

Inadequate treatment of early eyph111s

1s accepted as one of the most potent causes of relapse.
Infectuous mu�ocutaneous relapse or recurren.t second ..

ariea may be very extenelve and typ1eal,or localized
and difficult to classify.

The most troublesome is

the monorec1d1ve, or chancre redux, which may be almost
impossible to differentiate from a re1nfect1on chancre
except that 1t occure at the site of the previous
chancre.

Various attempts have been make to set up

suitable criteria for differentiating reinfection
from clinical relapse.

Such cr1ter1a have never been

ent1rely satisfactory, and are of epec1al importance
·for d1fferent1atlng reinfection from relapse 1n
intensive treatment cases.

In general the cr1ter1a f<r

cases receiving standard treatment are hardly suitable
for intensive treatment cases.

So Dr. Loren Shaffer

has set up a group of criteria of reinfection for
intensive treatment cases.
1) Accuracy of the orig1-.nal diagnosis of syphilis
assumed on the baBia of the adm1n1stration of
intensive treatment by organized hospital
or clinic.
2) Patient has remained seronegat1ve, or has
progressed to that state.

-263) Spinal fluid exam1nat1on negative prior to
second infection.

essential.)

(This 1a desirable but not

4) A lesion, cl1nlcally acceptable as a chancre.
develops at a site different from the first.
5) Patient is eeronegative, but darkfleld posi
tive at the time of the second 1nfect1on.
6) Def1n1te exposure history for second 1nfect1on.
(Ideally source for eeco�d 1nfeot1on should be

identified.)

7) If �eropositive at t1me of supposed second 1n
fect1on, patient should be held 1n 1solat1on
w1 thout treatment until after the prope._r interval,

at which time secondaries develop to establish
val:t.dity.
8) Seropos1tive cases of cllnlcally acceptable

primary lesions or cases present1ng character
istic secondary manifestations, with a history
or remains of a chancre, may be classified as
probably reinfection, if they fulfill the
above criteria.
Supposed reinfections occurring within slx months
after intenslve treatment is completed cannot be
differentiated from potential super-1nfectlons.

Cases

occurrlng at a later date may be assumed to be relnfect
ione. ( 61)

V

"Preeent acceptable methods of treat
ment with intensive the-raw"
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In the flret attempts to use massive arsen

otherapy, Chargin (9) treated a series of 25 pat
ients.

Neo-arsphenam1ne was the original drug used,

and in doses of 4 to 4.5 gms. adm1n1stered by a

continu ous intravenous drip system 1n a per iod of
five days.

As far as they have been able t o determine

some 8?% of these patients have been cured.

No addit

ional patients were treated until 193?, when th1s
method of treatment was re�1ved.

Eighty six patients

with primary and secondary syphills were treated with
neo-arsphenam1ne by the method used previously and
two year cures were reported .1n 91% of the cases.

When Jlapharsen was first used no experie nce with

1ts use in larger dosages was available.

The usual

recommended dose 1e l/10 of the dose of neo-arsphenamlne.

Thus a total dose of .4 gm or 400 mg. was decided upon
as the dosage amount for intravenous drip, w1th the

techn1que r emaining the same as that for neo-arephenam1ne.

Because the lower toxicity of Jlapharaen was finally

realized, and because the dosage employed allowed a

number of fallures of treatment, the dosage of Mapharsen
was increased in the intravenous drip to

·,oo

mg. and

then by slow degre es through :levels of 800, 1000 and
finally to the recommended dosage of 1200 mg.

The rate of adm1n1etrat1on was shown to be 240 mg.

-28per day for f1ve days, the 240 mg. be1ni dissolved in
2400 cc. of a 5% glucose solution and given at the
rate of 20 mg. per hour, continued over a period of
twelve hours.

This represents a dally dose of four

t1mee the amount usually injected (60 mg.) and a total
of twenty standard dosee in a period of flve days.
The injection is given from a gravity vacol 1ter at
an approximate rate of 3cc. p er minute.
In the accompanying chart are tabulated the
results of the New York treatment ser1es previously
deeer.
. 1b.ed

us1ng the slow continuous drip method.

Serles I with Kaphareen repre sents eases receiving

lees than 1,100 mg.

1n

f1Ye days, wh1le series II

received 1,100 mg. to 1,200 mg.
The above results pretty well parallel the
results now belng returned from various 1nten. s1ve
treatment centers set up about the country, using the
slow continuous drip.

Various modifications of the original New York
continuous drip method have been tried in different.
places throughout the eountry.

In Detroit, Shaffer

has developed a rapid dr1p modification which consists
of the adm1n1stration of approximately 1.2 mg. of
llapharsen per pound of body weight to a maximum dose
of 180 mg. dissolved 1n 1,000 cc. of 5% glucose
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Drug
Pat1ent-:s

Neoa�hena:m.tne
'N'umber

Satl!3factory
Pend1pg
Unsa t.1 sf.:ac'tory

I

l\.!apb�rsen

II

Percent

8'7

89

4

4

6

?

109 ?9
5

-3

82

83

�

9

�]&

i ...l!

138

99

-30solution.

It- is given by gl"a:v1ty {vacoliter) requires

60 to ?5 minutes for administration, and ls repeated ·.
dally for five days.
vision.·

It requires less hospital super

It .was hoped, even though the total dosage

was decidedly less, ?50 to 900 mg., than called for
1n the New York methods that its administration in a
shorter period of t1me, approx1mate1y one hour, m1ght
prove equally effective.
Results of th1a method, as reported by 1nvesti�
gators have closely paralleled the New York serlee
for primary cases, but has been decidedly 1nf�rior for
secondary cases.

Thls revealing fact would seem to

indicate the advisability of using larger dosages in
this method, at least 1n the treatment of the secondary
cases.
From the above there would seem to be little
difference between the advisability of using the slow
or rapid methods of intravenous drip therapy.
Another method of 1ntens1ve treatment has been the
multiple injection method.

Thia conelete of giving by

syr1nge technique (10 cc) a dose of 60 to 100 mg. of
Jlaphareen once or twice·da1ly and repeating the dosage
da1ly until a total of 1200 mg. has been adm1n1etered.
This method of g1v1ng 1ntene1ve therapy has been
reported by Thomae {61), and Schock (52).
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A dose of 60 mg. may be adm1n1stered twice dally
for ten days, 100 mg. twice dally for six days, or
100 mg. once daily for twelve days.

Schoch has never

used the latter method for ambulant cl1n1c patients.
Reports on the extensive use of this method are not
complete.

Thomas' report would indicate that the

1ncidence of serious reactions 1s at least as hlgh,
and probably higher, than with the slow drip adminis
tration.

Such methods are rather experimental, and

should not be used as general therapy. (53)
As to the uee of fever therapy in syphilis, Wagner
Jauregg was the first to use a form of hypertherm1a,
malaria, for treating dementia parplyt1ca.

Later this

treatment was tried 1n eaTly syphilis and found to be
successful.
the use

of

From malaria therapy we have drifted to
other fever producing implements, foreign

protein therapy, eg. typhoid-paratyphoid intravenous
1njections, hot baths, the 1nductotherm, and the
hypertherm.

Their value 1n central nervous system

eyphllls 1s unquestioned and 1nveat1gators have naturally
turned to them 1n the treatment of early syphilis.

It

was an .American dermatologist, J. F. Schamberg, who ae
long ago as 1926 report�d the beneficial effects of
hot baths 1n experimental rabbit syphllie.

In 1935

Epstein and Cohen and 1n 1936 Neymann, Lawless and
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Osborne found such treatment to be ineffective 1n
human syph111s.

This hae been confirmed by Boake,

Carpenter, jones, Kampmeier, Mccann, Warren and
Williams, and by Simpson, Rose and Kendall.

How

ever when this fever therapy is combined wlth chemo�
therapy it seems to be a different story.

A study of 141 patients with J&.pharsen and fever
1n 1941 1ndioated that very encouraging results
were obtalnable by using fever with .54 to .6 gm. of
llapharsen and no toxic reaction was observed. (64}
In a series of lnvestlgatlons conducted pri
marily as a study of quantitative serolog1c studies
in early syph1l1s, Simpson, Kendall and Rose, after
quite extensive studies using f1rst artlfic1al fever
alone, which they found to be ineffective for early
syphllls, and then 1nst1tut1ng a treatment of combined
fever and areenlcale, but conducted over a period of
weeks in courses of three hour sessions, twelve in
number; flnally attempted a single prolonged fever
treatment aceompanled by chemotherapy.

They reached

the conclusion by means of the following; repeated
determinations of the-serolog1c tlter by means of the
Kahn quantitatlve procegure, have shown that the pr�
greesive decline 1n t·lter to negat1v1 ty ls essentially
the same as that noted in lnd1v-tduals rece:tv1ng a

-33larger total amount of both art1f1c1al fever and
chemothe�apy over a longer period of time. {58)
If the above 1s true, the single fever treatment
combined w1th the chemotherapeutic attack would seem
to be the proper angle of attaek.
Because of the failure of induced fever alone (6)
to cure primary syphilis. 1n man, attempts have been
made to combine fever with subcuratlve doses of

arsenicals.
Jones (32) selected for study, patients with
clinical evidence of sypn111s

1n

1t ·s early stages,

who had received no previous anti-syphilitic treat
ment.

The diagnosis was verified by darkfleld and eer

olog1c examination.· He set up as contradictory to
this type of treatment, active pulmo�ary tuberculosis,
heart disease class II and clasR III, active renal
disease, per1vasoular disease of any type, and extreme
obesity.
His treatment cons1eted of the concurrent use ·of
fever and llapharsen.

The amount of the drug. and the

time of adm1n1strat1on in relation to the fever are
baaed on results obtained 1n the treatment of ex
perimental rabbit syph1l1s.

Because animal experiment

ation has shown, that fever increases the toxicity of
Ma.pharsen, subcu.rat1ve amounts of the drug were

-34employed for the treatment of the first series of
patients to avoid toxic reactions.
Three schedules of treatment were used which,
for the purpose of clarity, we shall summarize:.
a} Jlaphar sen: 1mg. per kg. body wt. adm1n1stered .
during the induction of the fever, but before the
temperature reaches 39.5 degrees

c.

The drug ie d15-

eolved 1n distilled water and injected intrava�ously.
b) Jlapha.rsen in the amount of

l.mg.

per kg. body

weight injected 1n the evening, and fever therapy is
Qarried out the follow1ng day.

A second intravenous

injection of 1.5 mR. Mapharsen per kg� b�dy weight
ls given at the termination of the fever.
c)-Jtapharsen in the amount of 2 m&!:. per kg. of
body weight administered at.the termination of the fever.
The drug is dissolved 1n d1stllled water as• in otner
eohedulee, then lt is added to 25-0'ml. o:f' a�$ glucose
in a .85% solution of Na Cl and 1njected intravenously
by the dr1p method.

The procedure requires about

fifteen minutes and is ueuallY completed by the time
the temperature has receded to 40.5- degrees C.
On the day or the fever treatment the patient 1s
placed in a fever cabinet early in the morn1np;.

He is

garefully checked throughout the cours.e of treatment,
for pulse. respiration and by means of the blood plasma,
for hie fluid balance.

To make up the fluid depletion
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intravenous solutions are admlnlstered.

After five

hours of fever t the patient is returned to his room.
He is required to rest 1n bed for several hours.

A

few of the patients leave the evenlng of the treat...
ment, but the majority rest the nlght 1n bed, and
leave on the·morn1ng following the treatment.
Patients are to be followed for a period of
five years, returning to the clinic weekly, during
the first eight weeks, monthly for the following six
months and every three months during the next year,
and annually thereafter.

At each follow up vlait ob

servations are made for the clinical evidence of
syph111s and blood ls taken for serology.

At.the time

of 1n1t1al treatment, spinal fluid is collected, or
on the first visit thereafter, for examination .

As far as they have been able to follow the

patients, the eche-0ule of treatment listed under c,
above, ha.a given the smallest percentage of relapses. (58)
One of the moat interesting proposals h�� also
been announced by Simpson, and calls for only one day
of treatment.

The method consists 1n the intramus

cular in.jection of 4 gr. of Bismuth subsa11oylate
twenty four hours before artificial fever therapy 1s
begun.

The patient.is then placed in a fever cabinet

and given continuous therapy for ten hours with

-3?-

temperatures from 105 degrees to 106 de�rees

Fa.

He

is also g1ven 120 .mg. of Xa.pharsen 1n divided dosaRe
by the syringe technique during the height of h1s
febrile reaction.

Simpson alms at reducing the time

of adm1n1strat1on of treatment from five days to one
day by the combined use of fever, arsenic and Bismuth.
Further reports on th1s method of treatment are
awaited with in terest. (54-55-56)
As th1s is written, there is alree,d::v some publ1ci ty
regarding the use of the new substance penicillin in
the treatment of syphilis.

Absolutely nothing can be

sa1d with assurance about the usefulness of penic1111n
in syphilis therapy except that the sub.iect 1s being
1nvest1gated.

The drug has been tried.in a very few

cases with immediate results.

No one has revealed

what the more important lasting effects will be.

As

a matter of fact there is not at present enough
pen1c1111n avallable to make possible an adequate trlal.
Results of the use of pen1c1111n by the armed
forces 1n the treatment of syphilis are unobtainable.
We can however �a1n some idea o� its usefulness by
reference to a study by Mahoney and Harris. (38)
A study of the usefulness of the drug was under�
taken after limited animal experimentation proved
that penicillin had some sp1roohet1c1da1 activity.
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Because of the general non toxic character of
the drug, a pilot study 1n four humans was run, after
a short experiment of 1ts effectiveness ln rabbit
syphilis had been determined.

The feeling w&�vtlia:t

observations could be made of the effectiveness of
the drug without placing the patient in je�pardy
because ultimate recovery of the patient could be
assured by conventional therapy, should pen1c1ll1n
prove ineffective.
The an1ma·. investigation showed one important
point, and that ls that the time dose relationship will
prove to be as important in this therapy as 1n the
use of other chemotherapeutic agents.
Four males were investigated.
tests ehowed them to be four plus.

Various serological
Each displayed a

single penile ulcer, which on darkf1eld showed ep1ro•
chetes.

The duration of the ulcers were eight days,

no other therapy was employed exe"S-pt pen1c1111n..
The treatment consisted 1n intramuscular in
ject1one of 25,000 unite at four hour intervals, night
and day, for eight days.

The total number of 1nject1ons

was forty eight and the total amount of the drug used
was 1,200,000 units.
of injection.

The gluteal muscle was the s1te

Darkf1eld examinations were done every

four hours, and after sixteen hours no more spirochetes
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could be seen.
Blood studies done daily, showed therapy was re
sponsible for a more or less rap1d and complete dis
appearance from the blood stream of the react1ijg sub
stance measured by serolog1c tests.
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On the preceding chart, I have tried to show
the main points of morbidity conclusions in the
'

articles published from the larger case series of
intensive treatments.

This condensation will give a

rough idea of the results obtained by a great number of investigators.
The mortality rate of routine therapy given to
patients of all ages and degree of deb1l1tv 1s less
than one third that of massive dose arsenotherapy
given to a sleeted group of young aaults with earlv
syphilis.

The mortality rate for a similarly selected

group under routine therapy is less than one seventh
that of massive dose therapv.

Fllrthermore the case

incidence of hemorrhagic encepnalitis with massive
dose arsenot~erapy is 60-70 tines that of routine
therapy. ( 24)
~very type and description of reaction is
watched for and recorded whenever 1ntens1ve tre atment
is used. and many reactions laid n.t the door of
intensive methods are reallv drug, method and tech~
n1que rec1ctions observed but not noted in other
standard treatrn~nt methods .

As an example we quote

the following.
Falk and Rattner observed this reaction in three
cases ln a series of 40~ cases at Cook County Hospital.
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Case 1_; Man 36 years of age, vn,th an eruption of
secondary svph1lis, on the firf't dav of treatment
w1 th

• 24 mg. of M:apharsen, immediately after with-

drawl of the neec_le from the vein, complained of
constricting pain in the chest, especially severe
in the precoroial area.

The pulse rate was 64, the

respirations forced and rapid and the heart tones
diminished.

Treatment with Morphine Sulfate af!orded

quick relief, and arsenotherapy was continued vn thout any further reoccurrence of pain.
Case II; A man 29 years of a.ge, vnth an eruption of
secondary syphilis, experienced sinnlar symptoms at
the end of the second day of treatment.

He complained

in addition of severe tightness in the abdomen.

He

responded to treatment with atropine alone, and treatment with arsenic was continued uneventfully .
Case III; A woman 26. years of age, receiving a second
five day course of arsenotherapy because of a sero loP:1c relapse, experienced similar symptoms, but to a
milder degree, which likevnse subsided after 1n.iect1011 of atropine ::mlfa.te.

She had not experienced

such sY1'Jlptoms during the first course of treatment
four months previously, although Ahe had been rest less and complained of pain in the arm end nausea
throughout both courseR.

-44-

Prats, Varas and Haraszt1 previously reported on
two cases of precord1al oppression occuring during arsenotherapy . ( l?)
Hemorrhagic encephali t1 s due to arsphena.mlne treatment is a very severe cond1 t1on, coming on fairly- rapidly within a few hours or days of administration, characterized by edema of the brain, capillary engorgement,
and minute hemorrhages. The patient becomes drowsy, apathetic, delerious, noisy, then coma,tose with stertorous
breathing, almost as 1n the case of alcoholic wet brain.
A convulsion may occur. Death may ensue w1th1n 48 hours .
Immediate injection of 5 to 10 minims of 1:1000 adren111n solution intravenously. repeated every few hours if
necessary, may save life. Hypertonic solutions ( 100 c.c.
of 10% saline or 251 sucrose) should also be given intravenously, followed by sodium thiosulphate. (63}
Two of the most alarming reactions which have followed the 1ntens1ve arsenotherapy of syphilis are, hemorrhagic encephalitis end peripheral neuritis. With heoarsphenamine, hemorrhagic encephalitis occurred twice in
111 patients and .in one instance proved fatal. In the
entire group treated with Mapharsen, both by continuous
drip , and multiple dose methods; the incidence of
hemorrhagic encephalitis was approximately 1 per
hundred patients treated and the mortality from this
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complication was ap proximately 1 per 300 patients.
Another serious reaction following the

11

flve day"

treatment 1s peripheral neuritis, which occurred among
35 per cent of the patients who received neo-arsphenam1ne and among 8 per cent of the 968 cases receiving
,,,
Mapharsen collected by Elliott and his co-workers.
Among the former group 1t was generally severe and
occasionally resulted 1n permanent disability.

knong

those rec.eiv1ng Mapharsen it was relatively mild with
no permanent sequelae reported.
Of the other treatment reactions, the toxlco dermas which occurred_ 1n approximately 45% of the
patients tre ·a ted with neo-arsphenamine and in about
10- 1 21 of those treated with Mapharsen are of interest
b~cau se of their frequency.

These reactions, generally

preceeded or accompanied by fever, seem analogous
to erythema of the ninth day . (44)

VII

"Soc1ologfc aspects"
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If 1t were possible to divide the country into
halves, isolating_ all syphilitics on one side and
those free of syphilis on the other, and by gradual
treatment render the syphilitics free of the disease
before allowing them to mingle with those who are
not infected until the disease had been eradicated
there would be no necessity for finding new methods
of treatment, our old ones would suff ice.
Since it is impossible to create a situation of
this kind, we must grope for other methods of
obtaining the same result.
Most _ people are familiar with the past methods
of treatment.

They realize that such methods are

time consuming at best, and that constant medical
supervision is necessary.

As a consequence, those

conscientious persons who will follow through a
scheduled method of treatment are few and the result
is that many infectious persons are left a.t large to
spread the disease.
Most people do not object to a short period of
hospitalization, especially when the majority of
the expense is borne by others .

For this reason there

is a true social value in an intensive method of
treatment.
At the present ti~e, a number of free clinics
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employing 1ntens1ve methods are scattered throughout
the country, and from reports they have submitted,
they have no difficulty in finding patients.

This

proves the point that people are really cognizant of
the fact that syph ilis is detrimental to their health,
and do wish to rid themselves of the disease .

It also

proves that the biggest draw back to medical eradication of the disease is the present slow treatment
method .
We c·an safely say, that if the newer methods
of treatment can accomplish the results we hope for,
the time

1

s not too far in the future , when we vdll

be able to wipe the name syphilis from the medical
lists of the country, just as surely as 1f we were
able to accomplish the seggregation mentioned in the
first paraP,raph of this section.
Such an accomplishment would be of social benefit
for 1t would add man h ours to industry; increase the
health ratio of the race; and raise the standard of
li v1ng of syphilis infested communl ties.

The ,incidence

of premature deaths from the ravages of late syphilis
would also glve us many brilliant minds lost to the
world by the ravages of the spirochete.

:VIII

"Summary and conclus1ons"
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In summarizing our investisat1nn of intensive
trec1.tnent we

!M'Y :=:'2.y,

that much is yet to be expected

in the way of . development .
··1e he.Ve seen, that e. firm r.istoricRl founde.t1on

has been built for its use, ao muat ~e preRent in any
ranical departure fro~ present methods .
Pharmacologic 1nvest1g0,tion has developed nevi
or_ improved drugs which are being used 1n this treat me nt
method, and which see~ ideally designed _fbr it.
An experimental groundwork h~s been lai d 1n
laboretory

a.no

cl1n1c to provide a war.king basis

for the pro~otion of be~ter techniques ,
It

hl ·S

a true ~oc 1ologi c aspect , and 11uci . . 1 s to

be ga1ne~ · in th1_s field!
As to the nethoc_ ·vhich will eventually find
universe.l use, 1t 1.s l-:rir1- to say c'lt tl11s tir~e , lf
the.t method 1-tas as yet been tried. · Through the use
of pen1c1ll1n, elthou~h t~is paper does not contain
extensive 1~vest1gat1on into its use, as such 1nformat1on is not yet R~a1lable, we h ope, beceuse of
its s1mpl1c1ty in use, and its efficacy 1n treating
other diseaRes, that it will eventually prove to be
the really effective mefrns of ercdicating syphilis .
This lf a relatively new concept , and as such
has far to go before ·the ultimate go·a1 is reached,
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but in evaluatinc the 'Nork done up to the present
time, I think we r:iay s?fely saJr, th2-t on an experi mental basis, 1ntens1ve treatment, proper ly conducted
is very effective, not unreasonably c:1angerous, and
should be used extensively 1f its administration
can be adequately supervisea by experts in the field .
We have seen throu~h this article, the pro ~inence played by the expression, "time ~ose relationship."

Using the tire aose relationship principle, a

large number of variations of the ititens1ve treatment
method have been tried.

They range all of the way

frorn one day of combined. fever and ersenical treat ment to six months of combined arsenical and bismuth
treatment.

Frankly no one knows yet what will prove to

be the best combination of ti Fe and dose, nor whether
fever or bismuth or bot11. will find a _pla_ce 1n the
optimum ~ethod.

One thing seems reasonably certain,

that after some years of careful study a riethod of
treatment which is mucr·, quicker than the present
standard

11

one year plus" P1ethod will become avail -

able .
At present the longest of the quick methods,
namely twenty six weeks of treatment with combined
l{aphatsen and bismuth seems the safest and at the
same time an effective Met,.10d of treatment of eFrlv
syphilis .

Many clinics no',7 employ this method .
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Lay people are often 1mpat1ent wltb the medical
prof'esaion for what seems undue caut1on 1n the matter
of treatment of eyphllls.

It should be remembered

that all ofthe articles wrltten 1n the various current
publications, which now hold the spotlight of populai:1ty, do not always carry art1cles by recognized lead
ers in medical fields.

It is the tendency of these

articles to capture public op1n1on by having a rather
melodramatic flare, which-w111 capture the imagination
and draw impossible pictures of present day methods
of treatment, praising their s1mpl1city of adm1n1strat1on and ava1lab111ty to the people 1n general.
1s, however, not the case.

SUoh

The magazine articles tried

a.nd true treatment is often st1ll in e-xperlmental phases
and ls as yet not ready for general public consump
tion.
Syphil1s ls a very slow acting disease, and 1ts
worst effects m93 appear ten to thirty years after 1n
fect1on.

It is this fact that phys1clans must con•

sider 1n evaluating new methods of treatment.

Mere

disappearance of the signs of the disease on the skin
and mucous membranes, a slngle negative blood test,
are far from a guarantee that the disease has been
el1m1nated from the body.

Phys1c1ana know fairly

well what the old standard methods will accomplish

-51-

w1th maximum eafe�y and comparatively small 1n
conven1ence to the patien t because we have had about
thlrty years of experience with these methods.

We

should not be chlded for taking a conservative at t1�
tude regarding methods with which we have had only
a relatively few years of exper1ence.

We are dealing

with human life, and 1n such a capacity, we cannot
afford to take chances.

When we accept a me thod of

treatment as s tandard, we must be sure of its
oapab111tles, mortallty and morbidity rate and
cl1n1cal results, otherwise, we are dealing with
potential death.

IX
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